Because of the nature of thrombocytosis, providers knew that autologous PRP was not an option. Instead, after obtaining informed consent from the patient and her daughter, the authors designed a treatment involving allogeneic PRP and artificial dermis.5 The treatment conformed to ethical guidelines and was approved by the institutional ethics committee. The patient signed a written release for the case and the relevant images.
Briefly, 20 mL of venous blood from the patient’s daughter was collected, 15 mL of which was used to prepare PRP. The other 5 mL was used to prepare autologous thrombin.6 The PRP was mixed with the autologous thrombin/calcium activator until a gelatinous mixture was obtained. In addition, testing for hepatitis B and C, HIV, and syphilis was conducted before application. The necrotic tissue on the ulcer surfaces was debrided, and the wounds were rinsed with iodine and saline. The unconsolidated portion of the PRP was injected into the inner walls of the ulcers, and the PRP gel was applied to the surface of the wounds. A wound-size sheet of PRP-impregnated artificial dermis (Pelnac; Gunze Limited, Kyoto, Japan) was placed on the wounds and covered with a polyurethane film (Mepore Film; Mölnlycke Wound Care AB, Gothenburg, Sweden). This PRP treatment was performed once a week for 4 weeks.
The patient reported notable pain relief and marginal erythema and edema reduction after the first PRP treatment. Fresh granulation tissue appeared, and the wounds contracted after the second PRP treatment. The wounds showed active granulation tissue growth, increasing in local angiogenesis and significant contraction after the third PRP treatment. In addition, the surface of the wound defects was even, and the lesions had decreased in size 2 weeks after the fourth PRP treatment (Figure 2A1, 2B1).
The PRP treatment was changed to a general dressing (including iodophor disinfection, saline cleaning, and gauze replacement). During this time, the patient discontinued the HU for 1 week and concealed this information from her doctors. Because of the short-term discontinuation and excellent results of the PRP treatment, it is unlikely that this drastically affected the patient outcomes.
The authors examined the ulcers at 1 month after the fourth PRP treatment and found that they were completely healed (Figure 2A2, 2B2). Providers followed up with the patient for 6 months, and; no recurrence was noted. During the follow-up period, the patient’s platelet levels were monitored regularly and remained around 300 to 500 × 109/L.
The clinical diagnosis of this patient was perplexing. She had been diagnosed with ET and was receiving HU treatment. Providers ruled out hypertension and thrombosis caused by ET as major contributors to ulcer formation because the patient’s previous ulcers healed after HU cessation and reformed after restarting HU therapy. Further, the patient’s platelet index and BP were well controlled during the administration of HU, so they were also unlikely to be the main cause of the ulcers. Based on these findings, the patient was eventually diagnosed with HU-associated ulcers, which is consistent with the literature.1
Hydroxyurea can inhibit the functions of ribonucleotide reductase, which in turn causes a decrease in cellular DNA production and induces cell death. In addition to inhibiting DNA synthesis, HU has significant antiangiogenic properties.7 In many patients, CLEUs are a severe adverse reaction to long-term HU treatment at a dose of at least 1 g/d. These ulcers tend to localize in the malleolar region and heal spontaneously when HU is discontinued.3 Treatment methods mostly involve discontinuation of drugs, as well as standard debridement and wound care. However, when medication cessation is not an option, a simple debridement and dressing may not heal these ulcers, which can become cancerous if they persist.7
To the authors’ knowledge, this is the first reported case of successful application of allogeneic PRP from lineal consanguinity in HU-related CLEUs with a favorable effect. Vascular ulcers are often associated with pain, and the researchers found that (consistent with previous reports8) PRP therapy was particularly effective for this patient’s pain.8 By promoting safe and natural healing, PRP offers a promising alternative to the current standard of care. The PRP is derived from density-gradient centrifugation of peripheral venous blood to obtain plasma rich in platelets. It contains a variety of growth factors, mesenchymal stem cells, fibroblasts, and leukocytes.9 Studies have confirmed that it can promote wound healing, improve angiogenesis, inhibit the growth of certain bacteria, and reduce postoperative pain.10,11 However, there is no uniform standard for the preparation and quality of PRP.
The success of this case may be attributable to a few different factors. First, PRP contains many bioactive molecules, such as fibroblast growth factors, mesenchymal stem cells, and leukocytes that promote wound healing and improve angiogenesis and pain relief.12 Further, allogeneic PRP offers all of the same functional factors as normal PRP.13 Third, artificial dermis improves nonhealing cutaneous ulcers, such as diabetic foot ulcers.5
This case provides the first evidence for the validity and utility of allogeneic PRP from a blood relative in healing HU-associated ulcers. However, future studies including more wounds are required to confirm the utility of this treatment and any adverse reactions. Nonetheless, further research is needed to investigate possible differences in clinical efficacy.
1. Quattrone F, Dini V, Barbanera S, Zerbinati N, Romanelli M. Cutaneous ulcers associated with hydroxyurea
therapy. J Tissue Viability 2013;22(4):112–21.
2. Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea
in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 2012;118(2):404–9.
3. Bader U, Banyai M, Böni R, Burg G, Hafner J. Leg ulcers in patients with myeloproliferative disorders: disease-or treatment-related? Dermatology 2000;200(1):45–8.
4. Stone T, Berger A, Blumberg S, et al. A multidisciplinary team approach to hydroxyurea
-associated chronic wound with squamous cell carcinoma. Int Wound J 2012;9(3):324–9.
5. Morimoto N, Ito T, Takemoto S, et al. An exploratory clinical study on the safety and efficacy of an autologous fibroblast-seeded artificial skin cultured with animal product-free medium in patients with diabetic foot ulcers. Int Wound J 2014;11(2):183–9.
6. Paola Romina A, Carias RBV, Teixeira MVT, Italo DCP, José Mauro G, Radovan B. Platelet-rich plasma
preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther 2013;4(3):67.
7. Lopes FC, Ferreira R, Albuquerque DM, et al. In vitro and in vivo anti-angiogenic effects of hydroxyurea
. Microvascular Res 2014;94:106–13.
8. Yotsu RR, Hagiwara S, Okochi H, Tamaki T. Case series of patients with chronic foot ulcers treated with autologous platelet-rich plasma
. J Dermatol 2015;42(3):288–95.
9. Marx RE. Platelet-rich plasma
(PRP): what is PRP and what is not PRP? Implant Dentistry 2001;10(4):225.
10. Serra R, Buffone G, Dominijanni A, Molinari V, Montemurro R, de Franciscis S. Application of platelet-rich gel to enhance healing of transmetatarsal amputations in diabetic dysvascular patients. Int Wound J 2013;10(5):612–5.
11. de Leon JM, Driver VR, Fylling CP, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma
gel. Adv Skin Wound Care 2011;24(8):357–68.
12. Aggarwal AK, Shashikanth VS, Marwaha N. Platelet-rich plasma
prevents blood loss and pain and enhances early functional outcome after total knee arthroplasty: a prospective randomised controlled study. Int Orthop 2014;38(2):387–95.
13. Rebulla P, Pupella S, Santodirocco M, et al. Multicentre standardisation of a clinical grade procedure for the preparation of allogeneic platelet concentrates from umbilical cord blood. Blood Transfus 2016;14(1):73–9.
Keywords:Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
artificial dermis; chronic ulcer; hydroxyurea; leg ulcer; platelet-rich plasma; thrombocythemia